title: Plasma arginine levels and the response to inhaled nitric oxide in neonates.
abstract: Inhaled nitric oxide (iNO) can be an effective vasodilator in pulmonary hypertension of the newborn (PHN). The aim of this study was to determine whether differences in arginine levels, from which endogenous NO is produced, explain the variability in response to NO and whether the arginine levels were lower in term and preterm infants with PHN than in infants without PHN (controls). We prospectively studied 30 infants (17 born preterm) with clinically diagnosed PHN and treated with iNO and 22 controls (14 born preterm). Three NO levels (10, 20, 40 ppm) were administered to the PHN infants to identify that associated with maximum oxygenation. Twenty-seven infants with PHN improved following iNO and had lower arginine levels than those infants who did not respond to iNO (p < 0. 05). No significant relationship, however, was noted between the arginine levels and either the magnitude of change in the oxygenation index in response to iNO or the NO level associated with maximum oxygenation. The median plasma arginine level prior to iNO of the PHN infants was 12.5 (range 2-53) mu mol/l, but not significantly lower than that of the controls (median 24, range 3-82 mu mol/l). We conclude that differences in plasma arginine levels are unlikely to explain the variation in response to iNO and that, although arginine levels tended to be lower in infants with PHN, this is not a consistent finding in either the term or preterm infants.
authors.affiliation: Department of Child Health, King's College Hospital, London, UK.
authors.forename: V
authors.initials: V
authors.lastname: Kavvadia
authors.forename: A
authors.initials: A
authors.lastname: Greenough
authors.forename: J
authors.initials: J
authors.lastname: Lilley
authors.forename: B
authors.initials: B
authors.lastname: Laubscher
authors.forename: G
authors.initials: G
authors.lastname: Dimitriou
authors.forename: F
authors.initials: F
authors.lastname: Boa
authors.forename: K
authors.initials: K
authors.lastname: Poyser
mesh_terms: D000280:Administration, Inhalation; D001120:Arginine / Q000097:blood*; D005317:Fetal Growth Retardation / Q000097:blood; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D009569:Nitric Oxide / Q000008:administration & dosage*; D010547:Persistent Fetal Circulation Syndrome / Q000097:blood*; D011446:Prospective Studies
chemical_list: D009569:Nitric Oxide; D001120:Arginine